������ý����

Michael Amoroso '00, who received a bachelor’s in biological sciences from ������ý����, has been named the president and chief executive officer of Precision BioSciences, a clinical stage biotechnology company. He will also serve as a member of the company’s board of directors. 

In a press release announcing the appointment, which is effective Oct. 15, Amoroso said he was excited for the opportunity to advance Precision’s genome editing platform, which is called ARCUS. 

Amoroso has significant operational experience leading organizations focused on cell and gene therapies. He brings extensive experience leading teams across research, clinical development, regulatory and medical affairs, and commercial operations. He has direct operational experience in the U.S. and major world markets.

“We are very pleased that Michael will lead the Precision BioSciences team as we embark on the next phase of the company’s growth and seek to maximize the opportunities for our ARCUS platform,” said Kevin Buehler, the chair of Precision BioSciences board of directors. “Michael’s deep commercial and operational expertise in hematology, oncology and gene therapy is an excellent fit for Precision and very relevant as we develop our strategy for late-stage clinical development and ultimately aim for commercialization.”

Amoroso is currently the president and chief executive officer of Abeona Therapeutics, a fully-integrated gene and cell therapy company. Prior to this role, he served as Abeona’s chief commercial officer and chief operating officer. He has held various senior-level executive positions at other leading biopharmaceutical companies, including most recently Kite Pharma.

In addition to his undergraduate degree from ������ý����, Amoroso received an Executive Master of Business Administration in Management from the Stern School of Business, New York University. 

������ý���� his new role, Amoroso said, “I’m particularly optimistic about the potential opportunity to bring novel cell therapies to patients who suffer from hematologic malignancies, and about the prospects of filing three Investigational new drug/clinical trial applications in the next three years for our gene editing treatments.”